https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-managing-pi3k-directed-triplet-therapy-and-treatment-related-toxicities2026-06-30T12:15:00Z2026-06-30T12:15:00Z https://www.onclive.com/view/why-pi3k-is-a-target-and-what-makes-duvelisib-different2026-06-30T12:05:00Z2026-06-30T12:05:00Z https://www.onclive.com/view/tarlatamab-mechanism-and-dellphi-305-trial-design2026-06-23T12:05:00.000Z2026-06-30T12:05:00Z https://www.onclive.com/view/optimizing-timing-of-adjuvant-cdk4-6-inhibitor-initiation-in-clinical-practice2026-06-30T12:05:00Z2026-06-30T12:05:00Z https://www.onclive.com/view/further-integrating-biosimilars-into-oncology-the-role-of-wyost-denosumab-bbdz-in-preventing-cancer-related-skeletal-events-with-bone-metastases-from-solid-tumors2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/defining-high-risk-hr-her2-early-breast-cancer-for-adjuvant-cdk4-6-therapy2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/tremelimumab-durvalumab-chemotherapy-vs-pembrolizumab-chemotherapy-in-1l-non-squamous-metastatic-nsclc-with-stk11-keap1-and-or-kras-mutations-interim-analysis-of-the-phase-2b-triton-study2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/dr-fakih-on-the-strategic-timing-and-concordance-of-biopsies-in-crc2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-triplet-therapy-implementation-and-management-after-prior-cdk4-6-inhibitor-exposure2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/the-us-landscape-and-the-regulatory-bottleneck-in-ptcl2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/administration-logistics-and-g-csf-prophylaxis-in-es-sclc2026-06-23T12:05:00.000Z2026-06-30T12:00:00Z https://www.onclive.com/view/fda-issues-crl-to-pet-diagnostic-imaging-kit-for-gallium-68-edotreotide-in-sstr-nets2026-06-29T22:20:00Z2026-06-29T22:20:00Z https://www.onclive.com/view/elisrasib-yields-durable-responses-in-pretreated-kras-g12c-mutant-nsclc2026-06-29T21:45:00Z2026-06-29T21:45:00Z https://www.onclive.com/view/unlocking-the-power-of-ctdna-for-residual-disease-resistance-monitoring-and-real-time-treatment-decisions-in-gi-cancers-with-christopher-lieu-md2026-06-29T20:03:56.570Z2026-06-29T20:03:56.570Z https://www.onclive.com/view/revumenib-intensive-chemotherapy-for-newly-diagnosed-acute-myeloid-leukemia-harboring-genetic-alterations-in-kmt2a-npm1-or-nup98-updated-phase-1-results-from-sndx-5613-07082026-06-29T20:00:00Z2026-06-29T20:00:00Z https://www.onclive.com/view/romiplostim-n01-promotes-platelet-recovery-after-unrelated-cord-blood-transplant-in-hematologic-malignancies2026-06-29T19:56:13.651Z2026-06-29T19:56:13.651Z https://www.onclive.com/view/dr-stein-on-the-key-clinical-implications-of-data-from-the-optima-trial-in-er-her2-early-breast-cancer2026-06-29T19:00:00Z2026-06-29T19:00:00Z https://www.onclive.com/view/dr-randall-on-the-use-of-tumor-informed-ctdna-deep-sequencing-for-osteosarcoma-risk-stratification2026-06-29T18:23:15.188Z2026-06-29T18:23:15.188Z https://www.onclive.com/view/dr-thomas-on-the-efficacy-of-first-line-ipatasertib-plus-pembrolizumab-in-hnscc2026-06-29T18:00:00Z2026-06-29T18:00:00Z https://www.onclive.com/view/multidisciplinary-tumor-board-integration-of-ctdna-results2026-06-29T17:22:00Z2026-06-29T17:22:00Z https://www.onclive.com/view/treatment-on-molecular-recurrence-and-access-barriers2026-06-29T17:20:49.355Z2026-06-29T17:20:49.355Z https://www.onclive.com/view/dr-orloff-on-key-findings-from-the-phase-2-3-optimum-02-trial-in-uveal-melanoma2026-06-29T17:00:00Z2026-06-29T17:00:00Z https://www.onclive.com/view/t-dxd-wins-eu-approval-for-previously-treated-her2-metastatic-solid-tumors2026-06-29T16:47:35.263Z2026-06-29T16:47:35.263Z https://www.onclive.com/view/dana-farber-uses-ai-to-design-proteins-that-could-make-cancer-drugs-safer-and-more-precise2026-06-29T16:00:00Z2026-06-29T16:00:00Z https://www.onclive.com/view/pembrolizumab-biosimilar-meets-primary-phase-1-and-phase-3-end-points-in-nsclc2026-06-29T14:13:57.711Z2026-06-29T14:13:57.711Z https://www.onclive.com/view/updated-overall-survival-and-long-term-transfusion-independence-from-the-phase-3-commands-trial-in-erythropoiesis-stimulating-agent-naive-patients-with-lower-risk-myelodysplastic-syndromes2026-06-29T13:51:08.041Z2026-06-29T13:51:08.041Z https://www.onclive.com/view/dr-fakih-on-practical-applications-of-liquid-and-tissue-biopsies-in-crc2026-06-29T13:40:01.733Z2026-06-29T13:40:01.733Z https://www.onclive.com/view/fda-approval-insights-decitabine-cedazuridine-plus-venetoclax-for-aml-with-courtney-d-dinardo-md-msce2026-06-29T13:00:00Z2026-06-29T13:00:00Z https://www.onclive.com/view/indirect-comparison-of-the-efficacy-of-zanubrutinib-vs-ibrutinib-and-acalabrutinib-in-treatment-naive-chronic-lymphocytic-leukemia-6-year-follow-up2026-06-29T12:32:38.243Z2026-06-29T12:32:38.243Z https://www.onclive.com/view/her2-positive-early-breast-cancer-applying-destiny-breast11-in-clinical-practice2026-06-29T12:05:00Z2026-06-29T12:05:00Z https://www.onclive.com/view/cll14-long-term-follow-up-and-ighv-guided-treatment-selection2026-06-29T12:05:00Z2026-06-29T12:05:00Z https://www.onclive.com/view/real-world-outcomes-of-zanubrutinib-vs-acalabrutinib-in-first-line-cll2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.onclive.com/view/t-dxd-plus-pertuzumab-sets-new-treatment-and-research-standards-in-her2-breast-cancer2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.onclive.com/view/first-line-cll-treatment-framework2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.onclive.com/view/her2-positive-early-breast-cancer-interpreting-destiny-breast11-trial-design2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.onclive.com/view/dr-specht-on-the-significance-of-data-for-mogamulizumab-vs-soc-in-denmark-for-patients-with-mf-ss2026-06-28T22:08:18.871Z2026-06-28T22:08:18.871Z https://www.onclive.com/view/dr-stuver-on-how-to-approach-pcptcl-nos-treatment-decision-making2026-06-28T19:00:00Z2026-06-28T19:00:00Z https://www.onclive.com/view/dr-prince-on-the-design-of-the-comparison-of-mavoric-and-real-world-vorinostat2026-06-28T16:59:24.274Z2026-06-28T16:59:24.274Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-6-212026-06-28T14:41:01.092Z2026-06-28T14:41:01.092Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-6-212026-06-28T13:42:04.972Z2026-06-28T13:42:04.972Z https://www.onclive.com/view/generic-enzalutamide-tablets-granted-tentative-fda-approval-for-prostate-cancer2026-06-28T12:35:34.415Z2026-06-28T12:35:34.415Z https://www.onclive.com/view/dr-mehta-shah-on-novel-ctcl-target-research2026-06-27T17:42:04.209Z2026-06-27T17:42:04.209Z https://www.onclive.com/view/st-001-nanofenretinide-shows-antitumor-activity-in-previously-treated-cutaneous-t-cell-lymphoma2026-06-27T17:30:58.904Z2026-06-27T17:30:58.904Z https://www.onclive.com/view/dr-mehta-shah-on-the-future-of-ctcl-novel-drug-development2026-06-27T17:25:59.432Z2026-06-27T17:25:59.432Z https://www.onclive.com/view/pegylated-interferon-alfa-2a-is-safe-and-tolerable-in-real-world-ctcl-study2026-06-27T17:13:00.228Z2026-06-27T17:13:00.228Z https://www.onclive.com/view/dr-scarisbrick-on-refining-mf-sezary-treatment-with-prosper-findings2026-06-27T17:05:15.155Z2026-06-27T17:05:15.155Z https://www.onclive.com/view/dr-scarisbrick-on-mogamulizumab-outcomes-in-prosper2026-06-27T16:53:36.863Z2026-06-27T16:53:36.863Z https://www.onclive.com/view/fda-approves-prefilled-pen-for-ropeginterferon-alfa-2b-njft-in-polycythemia-vera2026-06-27T16:33:24.748Z2026-06-27T16:33:24.748Z https://www.onclive.com/view/immune-and-single-cell-profiling-reveals-drivers-of-mogamulizumab-resistance-in-mf-and-ss2026-06-27T16:30:33.012Z2026-06-27T16:30:33.012Z https://www.onclive.com/view/duvelisib-nivolumab-immune-toxicities-limit-dosing-pretreated-ctcl2026-06-27T14:00:00Z2026-06-27T14:00:00Z https://www.onclive.com/view/mogamulizumab-improves-patient-reported-symptoms-and-hrqol-in-mycosis-fungoides-s-zary-syndrome2026-06-27T13:00:00Z2026-06-27T13:00:00Z https://www.onclive.com/view/chmp-recommends-pirtobrutinib-for-eu-approval-in-cll-across-all-lines-of-therapy2026-06-27T01:32:30.233Z2026-06-27T01:32:30.233Z https://www.onclive.com/view/extended-teclistamab-daratumumab-indication-approaches-eu-approval-in-r-r-multiple-myeloma2026-06-27T00:58:10.779Z2026-06-27T00:58:10.779Z https://www.onclive.com/view/dibotatug-is-safe-and-shows-activity-in-r-r-cytotoxic-t-nk-cell-lymphomas2026-06-27T00:33:08.579Z2026-06-27T00:33:08.579Z https://www.onclive.com/view/dr-querfeld-on-achieving-patient-satisfaction-with-mogamulizumab2026-06-26T23:51:12.065Z2026-06-26T23:51:12.065Z https://www.onclive.com/view/dr-querfeld-on-sequencing-strategies-for-mogamulizumab2026-06-26T23:37:35.145Z2026-06-26T23:37:35.145Z https://www.onclive.com/view/dr-nicolay-on-biomarkers-and-mechanisms-to-support-mogamulizumab2026-06-26T23:15:23.894Z2026-06-26T23:15:23.894Z https://www.onclive.com/view/dr-nicolay-on-the-biologic-response-to-mogamulizumab2026-06-26T23:13:56.770Z2026-06-26T23:13:56.770Z https://www.onclive.com/view/wccl-debate-how-to-classify-sptcl2026-06-26T22:51:56.450Z2026-06-26T22:51:56.450Z https://www.onclive.com/view/bi-1808-shows-efficacy-as-monotherapy-and-in-combination-with-pembrolizumab-in-t-cell-lymphomas2026-06-26T21:25:00Z2026-06-26T21:25:00Z https://www.onclive.com/view/real-world-mogamulizumab-elicits-durable-responses-in-pretreated-mycosis-fungoides-and-s-zary-syndrome2026-06-26T18:50:00Z2026-06-26T18:50:00Z https://www.onclive.com/view/dr-stein-on-test-directed-chemotherapy-in-er-her2-early-breast-cancer2026-06-26T16:42:19.067Z2026-06-26T16:42:19.067Z https://www.onclive.com/view/dato-dxd-earns-chmp-positive-opinion-for-first-line-metastatic-tnbc2026-06-26T16:05:51.992Z2026-06-26T16:05:51.992Z https://www.onclive.com/view/surgical-manual-from-roswell-park-created-to-advance-bladder-cancer-surgery-worldwide2026-06-26T16:00:00Z2026-06-26T16:00:00Z https://www.onclive.com/view/fda-accepts-third-rp1-bla-resubmission-with-nivolumab-in-advanced-melanoma2026-06-26T15:28:54.373Z2026-06-26T15:28:54.373Z https://www.onclive.com/view/live-tumor-board-translating-biomarker-insights-and-therapeutic-advances-into-endometrial-cancer-practice2026-06-26T14:13:18.431Z2026-06-26T14:13:18.431Z https://www.onclive.com/view/dr-morgans-on-the-clinical-significance-of-data-from-the-aracog-trial-in-prostate-cancer2026-06-26T13:00:00Z2026-06-26T13:00:00Z https://www.onclive.com/view/selecting-and-sequencing-first-line-therapy-in-alk-positive-nsclc2026-06-26T12:05:00Z2026-06-26T12:05:00Z https://www.onclive.com/view/top-study-design-and-results2026-06-26T12:03:00Z2026-06-26T12:03:00Z https://www.onclive.com/view/introduction-and-tp53-background-in-egfr-mutant-nsclc2026-06-26T12:01:00Z2026-06-26T12:01:00Z https://www.onclive.com/view/dr-nicholas-hornstein-on-ctdna-colorectal-cancer-why-better-drugs-are-coming2026-06-26T12:00:00Z2026-06-26T12:00:00Z https://www.onclive.com/view/optimizing-identification-and-molecular-testing-for-alk-positive-nsclc2026-06-26T12:00:00Z2026-06-26T12:00:00Z https://www.onclive.com/view/lorlatinib-vs-crizotinib-as-first-line-treatment-for-advanced-alk-non-small-cell-lung-cancer-7-year-update-from-the-phase-3-crown-study2026-06-26T12:00:00Z2026-06-26T12:00:00Z https://www.onclive.com/view/treatment-paradigm-evolution-and-systemic-therapy-selection-for-patients-with-desmoid-tumors2026-06-26T12:00:00Z2026-06-26T12:00:00Z https://www.onclive.com/view/tumor-informed-ctdna-sequencing-could-identify-osteosarcoma-relapse-months-before-radiographic-detection2026-06-26T12:00:00Z2026-06-26T12:00:00Z https://www.onclive.com/view/real-world-outcomes-among-medicare-beneficiaries-treated-with-first-line-bruton-tyrosine-kinase-inhibitors-for-chronic-lymphocytic-leukemia2026-06-26T12:00:00Z2026-06-26T12:00:00Z https://www.onclive.com/view/from-not-curable-to-may-be-curable-joshua-richter-md-on-the-new-reality-of-multiple-myeloma2026-06-26T01:03:52.382Z2026-06-26T01:03:52.382Z https://www.onclive.com/view/maic-shows-os-benefit-with-mogamulizumab-vs-vorinostat-in-cutaneous-t-cell-lymphoma-subtypes2026-06-25T23:57:12.570Z2026-06-25T23:57:12.570Z https://www.onclive.com/view/dr-girardi-on-properly-classifying-sptcl-vs-lymphoma2026-06-25T23:46:44.586Z2026-06-25T23:46:44.586Z https://www.onclive.com/view/wccl-debate-appropriate-changes-to-early-mf-treatment-strategy2026-06-25T23:45:26.688Z2026-06-25T23:45:26.688Z https://www.onclive.com/view/beylot-barry-moga-stop-and-mogamulizumab-retreatment-in-sezary-syndrome2026-06-25T23:26:14.471Z2026-06-25T23:26:14.471Z https://www.onclive.com/view/wccl-debate-treating-poor-mycosis-fungoides-prognosis-early2026-06-25T22:24:00Z2026-06-25T22:24:00Z https://www.onclive.com/view/dr-beylot-barry-on-patient-selection-and-limitations-of-moga-stop-in-sezary-syndrome2026-06-25T21:55:59.962Z2026-06-25T21:55:59.962Z https://www.onclive.com/view/quadruplet-regimens-and-t-cell-redirection-are-on-the-map-of-myeloma-management-strategies-with-chandler-park-md-muhamed-baljevic-md-facp2026-06-25T21:15:00Z2026-06-25T21:15:00Z https://www.onclive.com/view/tofacitinib-2-cream-yields-responses-and-is-safe-in-mycosis-fungoides2026-06-25T21:03:47.292Z2026-06-25T21:03:47.292Z https://www.onclive.com/view/analysis-identifies-potential-response-resistance-biomarkers-to-mogamulizumab-in-r-r-mycosis-fungoides-s-zary-syndrome2026-06-25T20:41:53.430Z2026-06-25T20:41:53.430Z https://www.onclive.com/view/revised-risk-stratifications-help-inform-the-use-of-adjuvant-cemiplimab-and-neoadjuvant-strategies-in-cutaneous-squamous-cell-carcinoma2026-06-25T20:06:38.557Z2026-06-25T20:06:38.557Z https://www.onclive.com/view/real-world-impact-of-atrial-fibrillation-on-cardiovascular-outcomes-and-healthcare-resource-utilization-in-patients-with-chronic-lymphocytic-leukemia2026-06-25T19:02:36.859Z2026-06-25T19:02:36.859Z https://www.onclive.com/view/champions-of-translational-research-scholars-recognized2026-06-25T15:00:00Z2026-06-25T15:00:00Z https://www.onclive.com/view/dr-morgans-on-the-cognitive-effects-of-darolutamide-vs-enzalutamide-in-prostate-cancer2026-06-25T13:55:41.219Z2026-06-25T13:55:41.219Z https://www.onclive.com/view/qol-efficacy-and-cost-considerations-help-drive-tki-treatment-selection-in-cml2026-06-25T13:00:00Z2026-06-25T13:00:00Z https://www.onclive.com/view/ripretinib-s-role-in-fourth-line-treatment-of-gist2026-06-18T12:05:00.000Z2026-06-25T12:05:00Z https://www.onclive.com/view/cabinet-trial-design-and-patient-population2026-06-25T12:05:00Z2026-06-25T12:05:00Z https://www.onclive.com/view/a-randomized-phase-iii-study-evaluating-izalontamab-brengitecan-iza-bren-versus-physician-s-choice-of-chemotherapy-in-patients-with-unresectable-locally-advanced-or-metastatic-triple-negative-breast-cancer-tnbc-2026-06-25T12:00:00Z2026-06-25T12:00:00Z https://www.onclive.com/view/intrigue-trial-insights-and-ctdna-applications2026-06-18T12:05:00.000Z2026-06-25T12:00:00Z https://www.onclive.com/view/daratumumab-retreatment-displays-activity-in-relapsed-myeloma-following-continuous-frontline-therapy2026-06-25T12:00:00Z2026-06-25T12:00:00Z https://www.onclive.com/view/frontmind-phase-3-study-of-tafasitamab-plus-lenalidomide-and-r-chop-for-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma2026-06-25T12:00:00Z2026-06-25T12:00:00Z https://www.onclive.com/view/evolving-understanding-and-treatment-landscape2026-06-25T12:00:00Z2026-06-25T12:00:00Z https://www.onclive.com/view/dr-morgans-on-the-design-of-the-aracog-trial-in-prostate-cancer2026-06-24T21:04:48.659Z2026-06-24T21:04:48.659Z https://www.onclive.com/view/dr-tolaney-on-the-fda-approval-of-first-line-sacituzumab-govitecan-plus-pembrolizumab-for-tnbc2026-06-24T20:45:21.430Z2026-06-24T20:45:21.430Z